Table 3.
Crude and Adjusted Odds Ratios of Sarcopenia According to 24-Hour Urinary Sodium Excretion
| Variable | Crude | Adjusted model | |||
|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | ||
| Total population (n=10,036) | |||||
| T1 | Reference | Reference | |||
| T2 | 1.12 (0.97–1.29) | 0.113 | 1.11 (0.95–1.29) | 0.178 | |
| T3 | 1.47 (1.29–1.68) | <0.001 | 1.49 (1.28–1.73) | <0.001 | |
| NAFLD absence (n=6,252)* | |||||
| T1 | Reference | Reference | |||
| T2 | 1.22 (0.99–1.51) | 0.061 | 1.41 (1.12–1.77) | 0.03 | |
| T3 | 1.34 (1.07–1.66) | 0.009 | 1.91 (1.49–2.45) | <0.001 | |
| NAFLD presence (n=3,784)* | |||||
| T1 | Reference | Reference | |||
| T2 | 0.85 (0.70–1.04) | 0.109 | 0.85 (0.68–1.05) | 0.845 | |
| T3 | 1.02 (0.85–1.22) | 0.856 | 1.09 (0.89–1.34) | 0.383 | |
Adjusted model, adjusted for age, sex, exercise, smoking, body mass index, hypertension, diabetes, dyslipidemia, aspartate aminotransferase†, alanine aminotransferase†, homeostasis model assessment of insulin resistance†, vitamin D, estimated glomerular filtration rate, Chronic Kidney Disease Epidemiology Collaboration, and appendicular muscle mass.
NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confidence interval; T1, lowest tertile, T2, middle tertile; T3, highest tertile.
*In subgroup analysis by NAFLD, aspartate aminotransferase, and alanine aminotransferase were excluded in adjusted model; †Log-transformed.